JP2008133278A5 - - Google Patents

Download PDF

Info

Publication number
JP2008133278A5
JP2008133278A5 JP2007300664A JP2007300664A JP2008133278A5 JP 2008133278 A5 JP2008133278 A5 JP 2008133278A5 JP 2007300664 A JP2007300664 A JP 2007300664A JP 2007300664 A JP2007300664 A JP 2007300664A JP 2008133278 A5 JP2008133278 A5 JP 2008133278A5
Authority
JP
Japan
Prior art keywords
group
substituent
atom
salt
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007300664A
Other languages
English (en)
Japanese (ja)
Other versions
JP4931775B2 (ja
JP2008133278A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2007300664A priority Critical patent/JP4931775B2/ja
Priority claimed from JP2007300664A external-priority patent/JP4931775B2/ja
Publication of JP2008133278A publication Critical patent/JP2008133278A/ja
Publication of JP2008133278A5 publication Critical patent/JP2008133278A5/ja
Application granted granted Critical
Publication of JP4931775B2 publication Critical patent/JP4931775B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007300664A 2004-08-06 2007-11-20 芳香族化合物 Expired - Fee Related JP4931775B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007300664A JP4931775B2 (ja) 2004-08-06 2007-11-20 芳香族化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2004230092 2004-08-06
JP2004230092 2004-08-06
JP2005090149 2005-03-25
JP2005090149 2005-03-25
JP2007300664A JP4931775B2 (ja) 2004-08-06 2007-11-20 芳香族化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005229066A Division JP4154613B2 (ja) 2004-08-06 2005-08-08 芳香族化合物

Publications (3)

Publication Number Publication Date
JP2008133278A JP2008133278A (ja) 2008-06-12
JP2008133278A5 true JP2008133278A5 (enExample) 2008-09-18
JP4931775B2 JP4931775B2 (ja) 2012-05-16

Family

ID=35508545

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005229066A Expired - Fee Related JP4154613B2 (ja) 2004-08-06 2005-08-08 芳香族化合物
JP2007300664A Expired - Fee Related JP4931775B2 (ja) 2004-08-06 2007-11-20 芳香族化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2005229066A Expired - Fee Related JP4154613B2 (ja) 2004-08-06 2005-08-08 芳香族化合物

Country Status (16)

Country Link
US (2) US8188277B2 (enExample)
EP (1) EP1773797A2 (enExample)
JP (2) JP4154613B2 (enExample)
KR (1) KR100927563B1 (enExample)
CN (1) CN1993339B (enExample)
AR (1) AR050448A1 (enExample)
AU (1) AU2005268030B2 (enExample)
BR (1) BRPI0514150A (enExample)
CA (1) CA2573223C (enExample)
IL (1) IL180884A (enExample)
MX (1) MX2007001215A (enExample)
MY (1) MY148905A (enExample)
RU (1) RU2416608C2 (enExample)
TW (1) TWI353983B (enExample)
WO (1) WO2006014012A2 (enExample)
ZA (1) ZA200700811B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2573223C (en) 2004-08-06 2013-05-21 Otsuka Pharmaceutical Co., Ltd. Aromatic compound
WO2006076706A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
EP1893609B1 (en) 2005-06-16 2009-11-18 Pfizer, Inc. N-(pyridin-2-yl)-sulfonamide derivatives
WO2007031791A1 (en) 2005-09-16 2007-03-22 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
ES2778846T3 (es) 2005-11-08 2020-08-12 Vertex Pharma Moduladores heterocíclicos de transportadores de casete de unión a ATP
JP5142513B2 (ja) * 2005-12-05 2013-02-13 大塚製薬株式会社 医薬
CA2630468C (en) 2005-12-05 2015-01-20 Otsuka Pharmaceutical Co., Ltd. Medicinal drug
ZA200804679B (en) 2005-12-08 2010-02-24 Millenium Pharmaceuticals Inc Bicyclic compounds with kinase inhibitory activity
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
NZ596889A (en) 2006-04-07 2013-06-28 Vertex Pharma Use of amide indole derivatives as modulators of ATP-binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CA2659512C (en) * 2006-06-06 2015-09-08 Critical Therapeutics, Inc. Novel piperazines, pharmaceutical compositions and methods of use thereof
US7943622B2 (en) 2006-06-06 2011-05-17 Cornerstone Therapeutics, Inc. Piperazines, pharmaceutical compositions and methods of use thereof
PT2799427T (pt) 2006-07-05 2018-10-16 Fibrotech Therapeutics Pty Ltd Compostos terapêuticos
AU2007286829B2 (en) * 2006-08-21 2013-05-02 Array Biopharma, Inc. 4-substituted phenoxyphenylacetic acid derivatives
US8269010B2 (en) * 2006-09-21 2012-09-18 Piramal Healthcare Limited 3-amino-pyridine derivatives for the treatment of metabolic disorders
AU2012202382B2 (en) * 2006-10-02 2014-06-26 Otsuka Pharmaceutical Co., Ltd. STAT3/5 activation inhibitor
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008116145A2 (en) * 2007-03-22 2008-09-25 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
CN102863432B (zh) 2007-05-09 2016-09-07 沃泰克斯药物股份有限公司 Cftr调节剂
JP2010536839A (ja) * 2007-08-17 2010-12-02 アストラゼネカ アクチボラグ 化合物979
WO2009076142A2 (en) 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
KR20150063170A (ko) 2007-12-07 2015-06-08 버텍스 파마슈티칼스 인코포레이티드 3-(6-(1-(2,2-디플루오로벤조[d][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
CN106432213A (zh) 2008-02-28 2017-02-22 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
FR2932483A1 (fr) * 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
MX2011005037A (es) 2008-11-21 2011-06-16 High Point Pharmaceuticals Llc Compuestos de adamantilo benzamida.
EA020460B1 (ru) 2009-01-12 2014-11-28 Пфайзер Лимитед Производные сульфонамида
JP5688918B2 (ja) * 2009-04-28 2015-03-25 大塚製薬株式会社 医薬組成物
WO2011046954A1 (en) * 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
IN2012DN03312A (enExample) 2009-10-22 2015-10-23 Fibrotech Therapeutics Pty Ltd
AR080057A1 (es) * 2010-01-29 2012-03-07 Otsuka Pharma Co Ltd Piridinas disustituidas como anticancerigenos
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
BR112012026255A2 (pt) 2010-04-07 2017-03-14 Vertex Pharma composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas
RU2745977C2 (ru) 2010-04-22 2021-04-05 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
ES2532356T3 (es) 2010-07-09 2015-03-26 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
EP2624833B1 (en) 2010-10-04 2014-12-10 Otsuka Pharmaceutical Co., Ltd. 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer
DK2806859T3 (da) 2012-01-25 2019-08-05 Vertex Pharma Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
JP5976224B2 (ja) * 2012-08-31 2016-08-23 ノバドラッグ, エルエルシー ウイルス性疾患を処置するためのヘテロシクリルカルボキサミド
SG11201503959VA (en) * 2012-11-20 2015-06-29 Merial Inc Anthelmintic compounds and compositions and method of using thereof
DK3068392T5 (da) 2013-11-12 2021-09-20 Vertex Pharma Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme
SG10201913575VA (en) 2014-04-15 2020-02-27 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
US10045979B2 (en) * 2014-05-19 2018-08-14 Merial Inc. Anthelmintic compounds
WO2016081556A1 (en) 2014-11-18 2016-05-26 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
EP3577103A1 (en) 2017-02-03 2019-12-11 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
WO2020059841A1 (ja) * 2018-09-21 2020-03-26 国立大学法人 長崎大学 プリオン病治療薬
CN111847474B (zh) * 2020-07-17 2021-09-28 浙江恒澜科技有限公司 一种Ti-ITQ-24沸石分子筛及其原位合成方法和应用
AU2023224057A1 (en) * 2022-02-28 2024-08-15 Sironax Ltd. Rip1 modulators, preparations, and uses thereof
CN116217511B (zh) * 2023-03-22 2024-04-19 沈阳药科大学 一种双靶点化合物及其制备方法和在制备sEH抑制剂与PPARs激动剂中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE629102A (enExample) * 1961-03-29
US3715375A (en) 1970-09-17 1973-02-06 Merck & Co Inc New diphenyl sulfones
NL7111711A (enExample) 1970-09-17 1972-03-21
GB1494117A (en) 1974-11-02 1977-12-07 Bayer Ag Process for the preparation of acid amides
DE2707659A1 (de) 1977-02-23 1978-08-24 Bayer Ag Selbstvernetzbare polyurethane
DE2707660C2 (de) 1977-02-23 1985-12-19 Bayer Ag, 5090 Leverkusen Abspalter- und Diolrest enthaltende Diisocyanat-Addukte, ihre Herstellung und Verwendung
DE2812252A1 (de) 1978-03-21 1979-10-04 Bayer Ag 1,2,4-triazol-blockierte polyisocyanate als vernetzer fuer lackbindemittel
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
EP0500495A3 (en) 1991-02-21 1993-04-07 Ciba-Geigy Ag Thermosetting composition
ES2108855T3 (es) 1992-07-21 1998-01-01 Ciba Geigy Ag Derivados de acido oxamico como agentes hipocolesteremicos.
HUT73813A (en) 1993-06-30 1996-09-30 Wellcome Found Anti-athero-sclerotic diaryl compounds, process to prepare them and pharmaceutical compositions contg. them
AU702423B2 (en) 1995-06-07 1999-02-18 Institute Of Materia Medica Chalcone retinoids and methods of use of same
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
ES2233025T3 (es) 1998-02-06 2005-06-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Agente inhibidores de la triptasa.
US6613769B1 (en) 1998-02-06 2003-09-02 Max-Planck-Gesellschaft zur Föderung der Wissenschaften. e.V. Tryptase inhibitors
AR015733A1 (es) * 1998-03-25 2001-05-16 Otsuka Pharma Co Ltd DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO.
TWI245035B (en) 1998-06-26 2005-12-11 Ono Pharmaceutical Co Amino acid derivatives and a pharmaceutical composition comprising the derivatives
CA2337098C (en) 1998-07-24 2008-08-05 Teijin Limited Anthranilic acid derivatives
CN1325380A (zh) * 1998-09-11 2001-12-05 味之素株式会社 苯衍生物和它们的药物用途
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20020065296A1 (en) * 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
WO2000046203A2 (en) 1999-02-04 2000-08-10 Millennium Pharmaceuticals, Inc. G-protein coupled heptahelical receptor binding compounds and methods of use thereof
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
US6159694A (en) * 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
CA2377771A1 (en) 1999-07-01 2001-01-11 Ajinomoto Co., Inc. Heterocyclic compounds and medical use thereof
JP2001089450A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ピリジン誘導体含有医薬製剤
JP2001089412A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
CA2400264A1 (en) 2000-02-15 2001-08-23 Teijin Limited Cancer remedy comprising anthranilic acid derivative as active ingredient
AU5741301A (en) 2000-05-22 2001-12-03 Aventis Pharm Prod Inc Arylmethylamine derivatives for use as tryptase inhibitors
GB0015205D0 (en) 2000-06-21 2000-08-09 Karobio Ab Bioisosteric thyroid receptor ligands and method
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
IL155097A0 (en) 2000-09-28 2003-10-31 Nanocyte Inc Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
AU2002223626A1 (en) 2000-10-20 2002-04-29 Novartis Ag Combinations of a thyromimetic compound and a statin
EP1211235A3 (en) 2000-11-30 2004-01-02 JFE Chemical Corporation Preparation process of 4,4'-Dicarboxydiphenyl ethers or derivatives thereof
JP2004269356A (ja) 2000-12-27 2004-09-30 Ajinomoto Co Inc 創傷部癒着防止剤
GB2374009A (en) 2001-02-12 2002-10-09 Novartis Ag Method of treating hair loss
OA12623A (en) 2001-06-20 2006-06-12 Pfizer Prod Inc Novel sulfonic acid derivatives.
CA2455773A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-aryl 7-aza¬2.2.1|bicycloheptanes for the treatment of disease
EP1438298B1 (en) 2001-10-22 2010-01-27 Pfizer Products Inc. Piperazine derivatives with ccr1 receptor antagonist activity
WO2003035602A1 (en) 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
US6852716B2 (en) 2002-02-15 2005-02-08 Pfizer Inc Substituted-aryl compounds for treatment of disease
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
JP2004035475A (ja) 2002-07-03 2004-02-05 Ajinomoto Co Inc TGFβ作用抑制剤
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
EP1651595A2 (en) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
PT1658263E (pt) 2003-07-24 2010-09-06 Leo Pharma As Novos compostos de aminobenzofenona
CA2573223C (en) 2004-08-06 2013-05-21 Otsuka Pharmaceutical Co., Ltd. Aromatic compound
CA2630468C (en) 2005-12-05 2015-01-20 Otsuka Pharmaceutical Co., Ltd. Medicinal drug
UA95978C2 (ru) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
TWI440638B (zh) 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物

Similar Documents

Publication Publication Date Title
JP2008133278A5 (enExample)
JP2007231005A5 (enExample)
RU2011129383A (ru) Производное амина, обладающее антагостической активностью в отношении рецептора npy y5
AU2006323700B2 (en) Diarylether derivatives as antitumor agents
JP2007508359A5 (enExample)
JP2009541403A5 (enExample)
JP2011524472A5 (enExample)
RU2008146088A (ru) Оксадиазолидиндионовое соединение
JP2010535722A5 (enExample)
JP2009543867A5 (enExample)
WO2003057688A3 (en) Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators
JP2011137006A5 (enExample)
WO2004014384A3 (en) Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
RU2007139634A (ru) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
JP2009535358A5 (enExample)
JP2005523310A5 (enExample)
JP2010536766A5 (enExample)
JP2004530641A5 (enExample)
JP2007246474A5 (enExample)
JP2010504930A5 (enExample)
PL1672017T3 (pl) Mieszaniny kauczukowe
JP2010536821A5 (enExample)
JP2007506721A5 (enExample)
JP2004535380A5 (enExample)
JP2005054150A5 (enExample)